MedTrace Logo

Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma

NCT04833504 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 39

Last updated 2025-07-16

No results posted yet for this study

Summary

This study is designed to monitor all patients exposed to CD19 CAR-T expressing IL7 and CCL19 for 5 years following infusion, to assess their long-term efficacy, including the CAR-vector persistence, the normal immunity rebuilding and the risk of delayed adverse events (AEs).

Conditions

  • Diffuse Large B-cell Lymphoma
  • Mantle Cell Lymphoma
  • Transformed Follicular Lymphoma
  • Primary Mediastinal Large B-cell Lymphoma

Interventions

BIOLOGICAL

CD19 CAR-T Expressing IL7 and CCL19

A fourth generation CD19 targeting CAR-T expressing IL7 and CCL19

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Principal Investigators

  • Wenbin Qian, Doctor · Zhejiang University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-22
Primary Completion
2023-09-22
Completion
2024-10-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04833504 on ClinicalTrials.gov